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Abstract
Aim: To provide an evidence-based scientific report on the efficacy of three common injection treatment
modalities for Lateral Epicondylalgia (LE). These injections are contemporary and frequently used in clinical practice.
Objective: To systematically locate and appraise RCTs (Randomised Controlled Trials) of three comparative
injection modalities (Corticosteroid Injection (CSI), Platelets Rich Plasma (PRP), and Autologous Blood Injection
(ABI) and to review their efficacy in the management of pain and dysfunction associated with LE.
Search strategy: RCTs that compare at least two of the three injections modalities and published from January
2005 to September 2015 were systematically searched. The following online search engines were utilised: The
Cochrane Central Register of Controlled Trials (Central), Web of Sciences, PubMed, CINAHL, MEDLINE, and
Academic Search Premier. The following search terms were used: “tennis elbow”, “lateral epicondylitis”,
“corticosteroid injection”, “autologous blood injection”, “platelets rich plasma” and “randomised controlled trial”. The
terms “tennis elbow” or “lateral epicondylitis” or “lateral epicondylalgia” were combined with each one of the injection
modalities and the term “randomised controlled trial”. Methodological assessment was conducted by applying Sign
50 tool and The Cochrane Collaboration’s tool for assessing risk of bias. This systematic review protocol was
conducted according to the standards presented in the Cochrane Handbook and recommendations in the Preferred
Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement.
Results: Seven RCTs were included within this review. Overall methodological quality was high, mostly level I
studies. Three RCTs compared the effects of PRP and ABI, three studies concerned the comparison between PRP
and CSI, and one RCT related to the effectiveness of ABI and CSI.
Conclusion: Corticosteroid injections failed to demonstrate long-lasting significant clinical effects in chronic LE.
However, PRP and ABI were shown to have a progressive and increasing effect from 6 months to one year following
the injections. PRP and ABI demonstrated comparable effects in terms of pain and function. Further studies are
warranted to justify the higher costs associated with the use of PRP.
Keywords: Tennis; Elbow; Lateral epicondylitis; Epicondylalgia;
Corticosteroid; Autologus blood; Randomized controlled trial; Platelet
rich plasma
Introduction
The main aim of this review is to systematically locate and appraise
published Randomised Controlled Trials (RCTs) that compare the
three injection modalities Corticosteroid Injection (CSI), Platelet Rich
Plasma (PRP) and Autologous Blood Injection (ABI)) for the
treatment of lateral epicondylalgia (LE). The intention was to provide a
robust scientific report of evidence-based knowledge to inform
healthcare providers. LE affects 1 to 3% of adults in the general
population each year [1-3]. The burden on the economic system is
substantial, with 5% of the affected working-age subjects reporting
work absence because of elbow symptoms in the past 12 months in
2012 [2,4].
This updated systematic review is justified on the basis of further
quality evidence being published since the review conducted in 2013
[5] to discern if there are any advances on current best practice
guidelines. They compared eight different treatments, including the
three injections in this review. They concluded that there were a
limited number of unbiased RCTs as evidence for the injection
therapies` effectiveness in the treatment of LE and advocated the need
for more large-size and good quality RCTs. Furthermore, they only
included RCTs that were conducted up to June 20, 2011.
Methods and Materials
The eligibility criteria for this review is illustrated in Table 1.
Inclusion Criteria Exclusion Criteria
Randomised controlled trials
Participants with Rheumatoid Arthritis,
history of elbow trauma and suspicion of
nerve involvement
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Comparative injection modalities
of (CSI, PRP and ABI) Studies published before 2005
Published between January 2005
and September 2015
Studies not published in the English
language
Published in the English language Involving subject with symptomsmanifesting for less than 3 months
Involving humans above the age
of 18
 
Table 1: Eligibility criteria list.
The following online search engines: The Cochrane Central Register
of Controlled Trials (Central), Web of Sciences, PubMed, CINAHL,
MEDLINE, and Academic Search Premier, using different
combination of the terms “tennis elbow” or “lateral epicondylitis” and
“randomised controlled trial”. The search began in June 2015 and was
regularly updated up to September 2015. Finally, seven trials were
included as illustrated in Figure 1.
Figure 1: Flow chart of the trials included.
Although local injections CSI, PRP, ABI, botulinum toxin,
hyaluronic acid, polidocanol, glycosaminoglycan, bone marrow
injection and prolotherapy can be utilised for LE [6]. In this review
only CSI, PRP, ABI will be discussed in details since they are
increasingly commonly utilised and contemporary injections [7]. CSI
is one of the most common injections used to manage cases of LE [4].
However, the exact mechanism of action of CSI in LE is still undefined
completely and further studies are warranted to assess why CSI can
lead to pain improvements in some chronic cases of LE [8].
Blood-based injections can deliver platelets-derived and blood-
derived mediators that can promote normal tendon healing [1]. These
mediators seem to enhance vascularity of the relatively hypo vascular
zones in the common extensor origin that have been described in a
previous study [9]. Formulating a robust and up-to-date comparative
review of these three injections will assist healthcare providers to
provide the best possible injection therapy and can delay the need for
surgical intervention.
Results
504 participants were included in the seven RCTs included in this
review. The majority (52%) of the participants were female.
Three trials compared CSI and PRP. They include one study in 2011
[10] who demonstrated that PRP had better outcomes at 6 and 12
months (P<0.001), and CSI better at 4 weeks. However, this was not
significant statistically (P = 0.206). Furthermore, PRP demonstrated
better outcomes at 2 years (P< 0.0001). In another trial in 2013 [11-13],
CSI resulted in better outcomes at 1 month (P<0.003), with no
difference between PRP and CSI groups at 3 months (P = 0.717). In the
study in 2015 [12], PRP had better outcomes in comparison with CSI
at 6 months (P<0.001).
Three trials compared PRP and ABI. They include one trial in 2011
[13] who reported no significant differences up to 6 months (p = 0.59).
Furthermore, in another trial in 2011 [13], PRP resulted in better
outcomes at 6 weeks (P˂0.05), but no significant differences at 3 or 6
months (P = 0.32). However, the trial in 2014 reported no significant
differences between ABI and PRP at 52 weeks (P = 0.662) [14,15].
Finally, one trial compared the effects of CSI in comparison with
ABI and ECSW [15]. They showed that CSI had better outcomes at 4
weeks (P<0.001), but ABI showed improved outcomes at 1 year
(P<0.001).
Discussion
Four trials including 250 participants received either PRP or CSI
[10,13] and were regarded as one trial as they are one follow up study.
The three trials differed in their inclusion criteria. Two trials used
clinical criteria only to include participants, except one trial [11] who
used Ultrasound (US) imaging as a criterion to diagnose and include
participants, as well as using US imaging an outcome measure. The
differences in the findings of the individual studies could have been
biased by the baseline differences in the treatment arms with respect to
underlying histopathological changes. In order to ensure homogeneity
of the future study population, modern imaging techniques such as US
imaging should be incorporated with pain and functional scores when
recruiting patients.
Formulations differed in these three trials for example 1 ml of 40 mg
triamcinolone acetonide was utilised in two studies [10,11], while the
other study [11] used 2 ml of methylprednisolone of 40 mg/ml.
Other formulations of CSI that have been described in the literature
are betamethasone (6 mg), dexamethasone (4-10 mg), and
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hydrocortisone (25 mg) [16,17]. These formulations not only differ in
their duration of action, but also differ in their water solubility and
their propensity to form particulate aggregates [18]. However, clinical
outcomes may be unaffected by different formulations [19].
Different concentrations and forms of local anaesthetics have been
described in the literature, but lidocaine (1–2%, without epinephrine)
is utilised most commonly [17]. Nevertheless, researchers have not
noticed any considerable difference in outcomes based on the
concentration or type of local anaesthetic used [17]. In addition,
lidocaine has been shown to have inhibitory effects on the proliferation
of tenocytes in an in vitro study [20].
A peppering technique was used in all of the three trials which
applied PRP and CSI, but two trials [11,12] did not specify the number
of penetrations performed in the CSI arms. Most researchers in these
four trials performed a single skin entry with 5 to 7 peppering
penetrations. In 2011 a study was conducted comparing the single-
injection with the peppering technique [21]. They concluded that the
single-injection technique has a better outcome than the peppering
technique. However, participants of this study were not blinded to the
technique received and there was a high loss to follow up. It has been
suggested that the peppering technique will lead to bleeding and create
channels in the degenerative myxoid tissue of LE which could
stimulate healing [22].
The number of CSI treatments to be given to an LE patient is
another topic debated in the literature. Most researchers allow the use
of 2 to 3 injections at two week intervals. However, up to 20 injections
have been reported, this can increase side effects such as skin atrophy
and depigmentation [2].
Two trials prepared PRP for their participants using similar
techniques [10,11], Approximately 3 mL PRP was obtained for each
patient in these two trials, and then to achieve a physiologic pH, the
prepared PRP was buffered using 8.4% sodium bicarbonate. The
differences in the study conducted in 2015 from the other two trials are
that: they collected 20 ml from the participants of PRP treatment arm,
used acid citrate as an anticoagulant, the speed of the centrifuge was
set at 1500, 2 ml was injected, and there was no mention of the use of
local anaesthetic [12].
Methods of isolation or centrifugation, single-spin (one step) and
double-spin (double step) separation techniques; type and operation of
the collecting tube; speed of the centrifuge; and other processes of
production, such as the use of activating agent, can result in different
amounts of platelets, White Blood Cells (WBCs), and growth factors in
PRP preparations [23,24]. Furthermore, the variations in WBCs and
other growth factors were observed in the same individual with
repetitive blood draws [23]. Inconsistency in the amount and
concentration of WBCs, VEGFs, and PDGFs in PRP samples taken for
different purposes have been observed previously [25]. All three trials
did not mention the concentration and amount of WBCs, Vascular
Endothelial Growth Factors (VEGFs) and Platelet-Derived Growth
Factors (PDGFs) obtained from their participants. The function of
WBCs depends on their concentration (it has been theorised that
WBCs can initiate an inflammatory phase which will subsequently
stimulate healing in chronic tendinopathies), and in order to achieve
beneficial effects of WBCs in PRP preparations, it is critical to define
the amount of WBCs in these preparations [26].
Defining PRP preparations according to platelet count can be
difficult as there is no consensus on adequate concentration which is
considered to be therapeutic for tissue healing [24]. In the literature,
many researchers assume platelets concentrations from 200 × 103
platelets/mL up to 1000 × 103 platelets/mL are considered to have
therapeutic effects, which means an increase from 2 to 8-fold from
native blood [24,26]. Higher volumes could be biologically
unfavourable [24].
A peppering technique was applied to all participants in the three
trials, but one trial [12] did not specify the number of penetrations
performed. Most researchers in these trials performed a single skin
entry with 5 to 7 peppering penetrations according to the technique
prescribed in 2006 [27]. A peppering technique will lead to bleeding
and create channels in the degenerative myxoid tissue of LE, which
could stimulate healing [22].
This microtrauma created by peppering at the site of injury may
have a clinical benefit, and hence it could be difficult to prove that the
observed results in the PRP treatment arms are due to the PRP
injections and not from the bleeding caused by the peppering
technique [1].
In order to ascertain the effects of dry needling and its possible
confounding effect with PRP injections, a study conducted an RCT,
comparing dry needling with PRP injections in 28 patients for around
19 months [28]. The difference in VAS scores at 2 and 6 months
between both groups was not significant, with slightly higher scores in
the PRP group. However, the small number of participants might have
impacted the power to determine a difference. Future large RCTs will
be of importance in determining any differences.
Only one trial, out of three trials that applied PRP and CSI and
stated that they did not use an activating agent prior to the PRP
injections [10]. Application of activating agents, such as calcium
chloride or thrombin, stimulate complete release of growth factors
from platelets [23]. Furthermore, it has been showed that with the use
of thrombin with different isolation devices in PRP preparations there
were discrepancies in the amount of platelet growth factors released,
which are crucial for tissue healing [23]. Therefore, as the studies
[11,12] did not mention the use of activating agents, it is difficult to
ensure that all PRP treatment arms of the three trials utilised a similar
amount of growth factors. Moreover, the amount of growth factors that
can released from PRP preparations varies considerably, from 1 to 25-
fold that of native blood [12].
In the trails that compared PRP and ABI, all participants were given
scan-guided injections except by one trial [15]. However, there is no
strong evidence in the literature to recommend one technique over the
other [8]. All participants in PRP and ABI trials had an unknown
number of penetrations by peppering technique except in one trial
[29], whereby no peppering was performed. Applying a peppering
technique might have confounded results achieved by the researchers
who applied it.
In the trial conducted in 2011 did not specify the amount of ABI
given to their participants, who received 2 injections of ABI at 0 and 1
months [14]. However, one injection of 2 ml and 3 ml of ABI were
given in the trial in 2014 and the trial in 2011 respectively [14,15]. In
addition to the platelets-derived growth factors present in ABI, there
are also other plasma-derived biologically active substances that can
effectively stimulate tendon healing [29].
With the exception of one trial, all trials that compared PRP and
ABI used local anaesthetics with the ABI [14]. This could be regarded
as another confounding variable, since the use of local anaesthetics
have been shown to inhibit proliferation of tenocytes in an in vitro
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study [30]. Furthermore, the use of blood-based preparations has
produced increasing levels of post-injection pain in comparison to CSI
[1]. Therefore, many clinicians still use local anaesthetics with different
injections in LE including ABI [31].
In addition to heterogeneity with trials comparing PRP and ABI,
differences in post-injection policies, particularly the physiotherapy
management, for example physiotherapy rehabilitation may have
confounded results. Physiotherapy modalities such as eccentric loading
can improve clinical outcomes in resistant cases of LE, either in
isolation or as an adjunct to other therapies including ABI [31].
The Cochrane Collaboration’s tool for assessing risk of bias and the
Sign 50 critical appraisal tool have been applied to all trials in this
review (Appendix).
Complications of injections reviewed
Overall, CSI, ABI, and PRP were safe injections and no serious
events such as hospitalization were reported. Temporary pain at the
injection site was the most common side effect reported in these trials.
Skin atrophy and depigmentation was reported following CSI use in
the one study [11], but patients with atrophy and depigmentation have
had CSI before. Another trial [16] also reported that 5% of their CSI
group had skin discolouration.
Furthermore, CSI is not effective in the long-term. This reported in
two trials [10,13].
Limitations of this review
The conclusion drawn from this review should be interpreted in
respect of some limitations.
The review was conducted by one author, including searches and
inclusion process, data extraction, quality assessment and critical
appraisal, and the reporting.
This might have induced bias, particularly with regard to quality
assessment of the trials included. However, the author has tried to
adopt an impartial and fair method of scoring and grading.
Furthermore, the second author, Lynne Gaskell has closely reviewed all
the steps during conducting this review at Salford University. Ideally,
systematic reviews should be conducted by the synergistic action of a
team of experts working together.
Heterogeneity of included trials in terms of different outcomes and
different methodologies did not allow quantitative synthesis of data
into a meta-analysis but led to a broad- based narrative review.
Another limitation of this review was the inclusion of studies that
were published in English language only. To conduct a comprehensive
review, studies published in other languages should have been
included.
Conclusion
CSI have been widely used in LE management, and are frequently
requested by patients. However, this review presents an argument
against their use for chronic LE, since no long term benefits were
found. This concurs with other reviews. While CSI have a well-
documented short-term benefit, they appear to have a detrimental
effect with longer follow up, such as an increase in recurrence rate
when compared with PRP and ABI.
With regard to PRP and ABI, the available high-quality literature in
this review has shown mixed results. The majority of trials found that
although CSI may provide better temporary relief of symptoms in
short-term, both PRP and ABI demonstrate improved outcomes from
6 months to 1 year. Therefore, current evidence supports that once
injection therapy is considered, blood-based preparations should be
considered over CSI. However, there was only one placebo-controlled
trial among all trials in this review to support this recommendation,
and they demonstrated no significant benefit in PRP in comparison to
CSI.
In this review, comparative trials that investigated PRP and ABI
efficacy have failed to show any significant difference between both
injections on different outcomes. The available data in this review are
limited by quality and size of study, and are currently insufficient to
recommend PRP over ABI. Therefore, in the light of the current
evidence, the use of PRP instead of ABI may be unjustified given the
higher cost associated with the preparations of PRP.
Implications for future research
Future larger controlled studies on blood-based preparations could
further enlighten aspects of these promising treatments in chronic LE.
Information regarding indications; the effects of presence and absence
of WBCs; number, time and frequency of injections required; and the
efficacy of platelets-rich and platelets-poor concentrations of PRP, will
clarify the different parameters of injections in the treatment of
chronic LE.
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